Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McGill University

$17,500.00

Prospective evaluation of gastrointestinal and genitourinary side effects of pelvic radiotherapy: Association between patient-reported outcomes and clinician-reported outcomes with a view to improving quality of care

FY 2021-22

Summary
Most patients who have pelvic radiotherapy (RT) as a treatment for cancer experience some degree of acute gastrointestinal (GI) and genitourinary (GU) toxicities. All patients must have access to well-coordinated, high-quality, multidisciplinary care. If physicians can anticipate, identify, and correctly manage symptoms, they can significantly improve patients' quality of life (QoL). In our study, All patients receiving standard or hypo-fractionated curative pelvic RT at McGill University Health Centre Radiation Oncology clinic between January 2022 to September 2022 are eligible. The standard treatment duration is three to five weeks. Patients will complete, through a mobile application (Opal) and in real-time, electronic patient-reported outcomes (PROs) questionnaires about acute GI/GU toxicities and quality of life (QoL). These questionnaires will be administered at baseline, weekly during RT, and at three subsequent time points. The treating physician will fill in the traditional intra-treatment forms simultaneously. We will assess the association between PROs and clinician reported outcomes (CROs) over time using Somers D statistic, Bowkers Symmetry test, and multilevel random effects regression models. This study aims to evaluate the feasibility of collecting PROs and CROs for GI/GU toxicities prospectively and in real-time in a busy tertiary care cancer center, explore influence of baseline characteristics on treatment-related toxicity and determine the ability to use PROs to triage patient symptoms by correlating PROs/CROs evolution of scores with management changes (changes in medications, ER visits, hospital admissions). To the best of our knowledge, no available prospective study has addressed these questions, and prominent gaps in the literature remain.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
467234
Name
Soliman Rania
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Prospective evaluation of gastrointestinal and genitourinary side effects of pelvic radiotherapy: Association between patient-reported outcomes and clinician-reported outcomes with a view to improving quality of care
Programtype2
Studentship Programs
Orgnameinp2
McGill University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clinician-Reported Outcomes; Electronic Questionnaires; Gastrointestinal; Genitourinary; Patient-Reported Outcomes; Pelvic; Prospective Evaluation; Quality Of Care; Radiotherapy; Real-Time; Side Effects
Abstract
Most patients who have pelvic radiotherapy (RT) as a treatment for cancer experience some degree of acute gastrointestinal (GI) and genitourinary (GU) toxicities. All patients must have access to well-coordinated, high-quality, multidisciplinary care. If physicians can anticipate, identify, and correctly manage symptoms, they can significantly improve patients' quality of life (QoL). In our study, All patients receiving standard or hypo-fractionated curative pelvic RT at McGill University Health Centre Radiation Oncology clinic between January 2022 to September 2022 are eligible. The standard treatment duration is three to five weeks. Patients will complete, through a mobile application (Opal) and in real-time, electronic patient-reported outcomes (PROs) questionnaires about acute GI/GU toxicities and quality of life (QoL). These questionnaires will be administered at baseline, weekly during RT, and at three subsequent time points. The treating physician will fill in the traditional intra-treatment forms simultaneously. We will assess the association between PROs and clinician reported outcomes (CROs) over time using Somers D statistic, Bowkers Symmetry test, and multilevel random effects regression models. This study aims to evaluate the feasibility of collecting PROs and CROs for GI/GU toxicities prospectively and in real-time in a busy tertiary care cancer center, explore influence of baseline characteristics on treatment-related toxicity and determine the ability to use PROs to triage patient symptoms by correlating PROs/CROs evolution of scores with management changes (changes in medications, ER visits, hospital admissions). To the best of our knowledge, no available prospective study has addressed these questions, and prominent gaps in the literature remain.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Soliman, Rania
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~